Cannabis Systematics at the Levels of Family, Genus, and Species John M. McPartland Cannabis and Cannabinoid Research, 2018, Volume 3.1, 203- Doi : 10.1089/can.2018.0039 Abstract New concepts are reviewed in Cannabis systematics, including phylogenetics and nomenclature. The family Cannabaceae now includes Cannabis, Humulus, and eight genera formerly in the Celtidaceae. Grouping Cannabis, Humulus, and Celtis actually goes back 250 years. Print fossil of the extinct genus Dorofeevia (=Humularia) reveals that Cannabis lost a sibling perhaps 20 million years ago (mya). Cannabis print fossils are rare (n = 3 worldwide), making it difficult to determine when and where she evolved. A molecular clock analysis with chloroplast [...]
Lire la suiteMedicinal Cannabis on Prescription in The Netherlands : Statistics for 2003–2016 Bas de Hoop, Eibert R. Heerdink, and Arno Hazekamp Cannabis and Cannabinoid Research, 2018, Volume 3.1, Doi : 10.1089/can.2017.0059 In 2003, the Netherlands started one of the first National medicinal cannabis programs in the world, where patients are provided with pharmaceutical-grade cannabis of standardized cannabinoid composition. The program is overseen by the Office of Medicinal Cannabis (OMC), which is part of the Ministry of Health, while cultivation, packaging, lab testing, and distribution are performed by contracted specialized companies. Medicinal cannabis is available on prescription only and can be dispensed by all Dutch pharmacies. [...]
Lire la suiteMyorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial Aleksandra Nitecka-Buchta, Anna Nowak-Wachol, KacperWachol, KarolinaWalczynska-Dragon, Paweł Olczyk, Olgierd Batoryna, Wojciech Kempa and Stefan Baron Journal of Clinical Medicine, 2019, 8, 188, 1-17. doi : 10.3390/jcm8111886 Abstract Background : The healing properties of cannabidiol (CBD) have been known for centuries. In this study, we aimed to evaluate the efficiency of the myorelaxant effect of CBD after the transdermal application in patients with myofascial pain. Methods : The Polish version of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD Ia and Ib) was used. A total of 60 patients were enrolled [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C - ISSN 1756-8919 “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]
Lire la suiteStudy protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449 Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]
Lire la suiteAyahuasca : Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness Jonathan Hamill, Jaime Hallak, Serdar M. Dursun and Glen Baker Current Neuropharmacology, 2019, 17, 108-128. Doi : 10.2174/1570159X16666180125095902 Abstract Background : Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) andleaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use [...]
Lire la suiteAntidepressive and anxiolytic effects of ayahuasca : a systematic literature review of animal and human studies Rafael G. dos Santos, Flavia L. Osorio, José Alexandre S. Crippa, Jaime E.C. Hallak Revista Brasileira de Psiquiatria, 2016, 38, 65–72 doi:10.1590/1516-4446-2015-1701 ABSTRACT Objective : To conduct a systematic literature review of animal and human studies reporting anxiolytic or antidepressive effects of ayahuasca or some of its isolated alkaloids (dimethyltryptamine, harmine, tetrahydroharmine, and harmaline). Methods : Papers published until 3 April 2015 were retrieved from the PubMed, LILACS and SciELO databases following a comprehensive search strategy and using a predetermined set of criteria for article selection. Results : Five hundred and [...]
Lire la suiteTherapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical Trial Nadia Solowij, Samantha J. Broyd, Camilla Beale, Julie-Anne Prick, Lisa-marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J. Croft, Jennifer H. Martin, and Murat Yücel Cannabis and Cannabinoid Research, 2018, 3, 1,21-35 Doi : 10.1089/can.2017.0043 Abstract Introduction : Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While D9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to [...]
Lire la suiteProlonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users Camilla Beale, Samantha J. Broyd, Yann Chye, Chao Suo, Mark Schira, Peter Galettis, Jennifer H. Martin, Murat Yücel and Nadia Solowij Cannabis and Cannabinoid Research, 2018, 3, 1, 94-107. Doi : 10.1089/can.2017.0047 Abstract Introduction : Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While adverse impacts of cannabis use are generally attributed to D9 tetrahydro-cannabinol, emerging naturalistic evidence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis use, including protection from hippocampal volume loss. This study examined whether prolonged administration of CBD to regular cannabis users [...]
Lire la suite